You just read:

New Subanalyses of RE-LY® Trial Evaluate PRADAXA in Subsets of Patients with Non-Valvular Atrial Fibrillation

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Nov 14, 2011, 09:30 EST